The results showed that SPRED3 expression significantly differed according to clinical stage (T1/2 vs. T3/4), lymph node invasion (N0 vs. N1), primary tumor tissue type, external thyroid gland invasion, tumor residue, tumor location and previous thyroid history (Table 1). This evidence concerns the gene SPRED3 and neoplasm.